Have a personal or library account? Click to login
A comparison of selected dosimetric parameters of two Hodgkin Lymphoma radiotherapy techniques with reference to potential risk of radiation induced heart disease Cover

A comparison of selected dosimetric parameters of two Hodgkin Lymphoma radiotherapy techniques with reference to potential risk of radiation induced heart disease

Polish Journal of Medical Physics and Engineering
Volume 24 (2018): Issue 3 (September 2018)
By: Elias Alibeyki,  Saeid Karimkhani,  Sepide Saadatmand and  Parvaneh Shokrani  
Open Access
|Oct 2018

References

  1. [1] Halperin EC, Brady LW, Perez CA, et al. Perez & Brady’s Principles and Practice of Radiation Oncology. Wolters Kluwer Health; 2013.
    Search in Google ScholarBack to article
  2. [2] Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081-3087.10.1200/JCO.2002.12.10112118021
    Search in Google ScholarBack to article
  3. [3] Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-862.10.1016/j.ijrobp.2013.05.00523790512
    Search in Google ScholarBack to article
  4. [4] Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439.10.1200/JCO.2003.07.13112885835
    Search in Google ScholarBack to article
  5. [5] Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154(1):23-31.10.1111/j.1365-2141.2011.08713.x21539537
    Search in Google ScholarBack to article
  6. [6] Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signalg. 2011;15(7):1945-1956.10.1089/ars.2010.3742315911321091078
    Search in Google ScholarBack to article
  7. [7] Emami B. Tolerance of normal tissue to therapeutic radiation. Rep Rradiother Oncol. 2013;1(1):123-127.
    Search in Google ScholarBack to article
  8. [8] Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3):S77-S85.10.1016/j.ijrobp.2009.04.09320171522
    Search in Google ScholarBack to article
  9. [9] Hahn E, Jiang H, Ng A, et al. Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. Int J Radiat Oncol Biol Phys. 2017;98(5):1116-1123.10.1016/j.ijrobp.2017.03.02628721895
    Search in Google ScholarBack to article
  10. [10] Jakacki RI, Goldwein JW, Larsen RL, et al. Cardiac dysfunction following spinal irradiation during childhood. J Clin Oncol. 1993;11(6):1033-1038.10.1200/JCO.1993.11.6.10338501489
    Search in Google ScholarBack to article
  11. [11] Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308-1315.10.1200/JCO.2008.20.226720142603
    Search in Google ScholarBack to article
  12. [12] Hoppe R. Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl 1):S115-S118.10.1093/annonc/8.suppl_1.S115
    Search in Google ScholarBack to article
  13. [13] Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108.10.1200/JCO.2002.08.02111956271
    Search in Google ScholarBack to article
  14. [14] Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.10.1093/jnci/djk02917284715
    Search in Google ScholarBack to article
  15. [15] Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(1):199-205.10.1016/j.ijrobp.2010.09.00721481723
    Search in Google ScholarBack to article
  16. [16] Engert A, Pluetschow A, Eich HT, et al. Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). Blood. 2005;106(11):2673.10.1182/blood.V106.11.2673.2673
    Search in Google ScholarBack to article
  17. [17] Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13(suppl 1):79-83.10.1093/annonc/13.S1.79
    Search in Google ScholarBack to article
  18. [18] Hoskin P, Díez P, Williams M, et al. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol. 2013;25(1):49-58.10.1016/j.clon.2012.07.01122889569
    Search in Google ScholarBack to article
  19. [19] Herst J, Crump M, Baldassarre F, et al. Management of Early-stage Hodgkin Lymphoma: A Practice Guideline. Clin Oncol. 2017;29(1):e5-e12.10.1016/j.clon.2016.09.00627697411
    Search in Google ScholarBack to article
  20. [20] Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.10.1200/JCO.2007.15.100118838714
    Search in Google ScholarBack to article
  21. [21] Koh E-S, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13.10.1186/1748-717X-2-13184751717362522
    Search in Google ScholarBack to article
  22. [22] Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):268-276.10.1016/j.ijrobp.2011.05.05422079733
    Search in Google ScholarBack to article
  23. [23] Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. Wiley; 2011.10.1002/9780471420194.tnmc26.pub2
    Search in Google ScholarBack to article
  24. [24] Khan FM, Gibbons JP. Khan’s The Physics of Radiation Therapy. Wolters Kluwer Health; 2014.
    Search in Google ScholarBack to article
  25. [25] Barrett A, Dobbs J, Roques T. Practical Radiotherapy Planning Fourth Edition. Taylor & Francis; 2009.10.1201/b13373
    Search in Google ScholarBack to article
  26. [26] Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys. 2005;61(3):842-850.10.1016/j.ijrobp.2004.07.70815708264
    Search in Google ScholarBack to article
  27. [27] van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34(3):235-243.10.1200/JCO.2015.63.444426573075
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/pjmpe-2018-0017 | Journal eISSN: 1898-0309 | Journal ISSN: 1425-4689
Journal RSS Feed
Language: English
Page range: 121 - 126
Submitted on: Mar 2, 2018
Accepted on: Jun 28, 2018
Published on: Oct 4, 2018
Published by: Polish Society of Medical Physics
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cardiac toxicity,
Hodgkin lymphoma,
treatment planning,
radiotherapy
Related subjects:
Medicine,
Biomedical engineering,
Physics,
Technical and applied physics,
Medical physics

© 2018 Elias Alibeyki, Saeid Karimkhani, Sepide Saadatmand, Parvaneh Shokrani, published by Polish Society of Medical Physics
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 24 (2018): Issue 3 (September 2018)Next article